786例慢性乙型肝炎患者恩替卡韦基因型耐药突变及特征分析

肝脏 ›› 2021, Vol. 26 ›› Issue (12): 1344-1347.

786例慢性乙型肝炎患者恩替卡韦基因型耐药突变及特征分析

岳秀娟, 李庆, 王珊珊, 陈德喜, 石英

100069 首都医科大学附属北京佑安医院(岳秀娟,李庆,王珊珊,陈德喜,石英),北京市肝病研究所(王珊珊,陈德喜,石英)

收稿日期:2021-01-19 发布日期:2022-01-13
通讯作者: 石英,Email:yingshi@ccmu.edu.cn
基金资助:
国家自然科学基金(81870424);北京市自然科学基金(7182072);北京市教育委员会科技计划重点项目(KZ201810025037)

Genotypic analysis of entecavir-resistant mutation in 786 patients with chronic hepatitis B

YUE Xiu-juan, LI Qing, WANG Shan-shan, CHEN De-xi, SHI Ying

Beijing You'an Hospital, Capital Medical University, Beijing 100069, China;
Beijing Institute of Hepatology, Beijing 100069, China

Received:2021-01-19 Published:2022-01-13
Contact: SHI Ying, Email: yingshi@ccmu.edu.cn

摘要/Abstract

摘要： 目的了解恩替卡韦耐药突变特点。方法选取2009年1月至2020年10月北京佑安医院检测的恩替卡韦基因型耐药的CHB患者786例,分析耐药情况。结果 786例恩替卡韦基因型耐药患者中HBV基因型C亚型705例(89.7%),B亚型79例(10.1%),D亚型2例(0.3%)。共发现21种耐药突变类型,其中rtL180M+rtM204V(或者rtM204I)+rtV173耐药突变类型219例(27.9%),rtL180M+rtM204V(或者rtM204I)+rtT184耐药突变类型218例(27.7%),rtL180M+rtM204V+rtS202耐药突变类型175例(22.3%),rtL180M+rtM204V+rtS202+rtT184耐药突变类型52例(6.6%),rtL180M+rtM204V+rtM250耐药突变类型44例(5.6%),其他16种耐药突变类型共78例(9.9%)。结论恩替卡韦基因型耐药患者中,HBV基因型C亚型占绝对优势,rtL180M+rtM204V(或者rtM204I)+rtV173突变类型数量最多,rtT184位点突变数量最多。

关键词: 慢性乙型肝炎, 恩替卡韦, 基因分型, 耐药突变

Abstract: Objective To investigate the genotypic features of entecavir-resistant mutation in patients with chronic hepatitis B (CHB) in our hospital, and provide clinical data about characteristics and trends of entecavir-resistant mutation. Methods A total of 786 patients with entecavir-resistant mutation admitted to our hospital from January 2009 to October 2020 were selected. The drug-resistant situation were further analyzed. Results Among the 786 entecavir-resistant mutation patients, the numbers of hepatitis B virus (HBV) C genotype, HBV B genotype and HBV genotype were 705 (89.7%), 79 (10.1%) and 2 (0.3%), respectively. Twenty-one drug-resistant mutation types were found. The numbers of rtL180M + rtM204V (or rtM204I) + rtV173, rtL180M + rtM204V (or rtM204I) + rtT184, rtL180M + rtM204V + rtS202, rtL180M + rtM204V + rtS202 + rtT184, rtL180M + rtM204V + rtM250 mutation types were 219 (27.9%), 218 (27.7%), 175 (22.3%), 52 (6.6%) and 44 (5.6%) respectively. There were other 16 mutation types with a total number of 78 (9.9%). Conclusion HBV genotype C are the most common genotype among patients with entecavir-resistant mutation in our hospital. The rtL180M + rtM204V (or rtM204I) + rtV173 is the most prevalent mutation type and rtT184 is the most prevalent mutation site. Our research can help people understand the HBVgenotypes and mutation types of CHB patients with entecavir-resistant mutation in our hospital.

Key words: Chronic hepatitis B, Entecavir, Genotype, Drug-resistant mutation

岳秀娟, 李庆, 王珊珊, 陈德喜, 石英. 786例慢性乙型肝炎患者恩替卡韦基因型耐药突变及特征分析[J]. 肝脏, 2021, 26(12): 1344-1347.

YUE Xiu-juan, LI Qing, WANG Shan-shan, CHEN De-xi, SHI Ying. Genotypic analysis of entecavir-resistant mutation in 786 patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2021, 26(12): 1344-1347.

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南. 中国肝脏病杂志(电子版),2019,11:5-27.
[2] 俞杨,杜同信,王自正, 等.1例未经恩替卡韦治疗的慢性乙肝患者出现恩替卡韦基因型耐药的分析. 国际检验医学杂志,2012,33:2943+2945.
[3] 王珠,王武.慢性乙型肝炎患者拉米夫定和恩替卡韦基因型耐药突变特征分析. 中国医药导报,2012,9:97-98.
[4] 刘妍,李庆虹,李乐, 等.慢性HBV感染患者恩替卡韦基因型耐药突变特征分析. 解放军医学杂志,2010,35:621-624,628.
[5] 万里江,朱珍.恩替卡韦耐药的乙型肝炎患者HBV聚合酶基因变异分析. 临床医药文献电子杂志,2019,6:77+81.
[6] 刘璐洁,刘妍,陈容娟, 等.乙型肝炎病毒新型恩替卡韦耐药突变rtL180M+A186T+M204V的鉴定. 解放军医学杂志,2019,44:197-202.
[7] 王富珍,郑徽,孙校金,等.中国控制乙型病毒性肝炎的成就与展望. 中国疫苗和免疫,2019,25:487-492.
[8] 刘芬,王系伟.恩替卡韦初始抗病毒治疗慢性乙型肝炎患者5年发生基因型耐药1例. 中华肝脏病杂志,2013,21:781-782.
[9] 郭晓凤,张超贤,刘雁, 等.恩替卡韦治疗后乙型肝炎病毒多聚酶区耐药基因检测分析. 中国医学科学院学报,2013,35:444-446.
[10] Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology,2009,49:1503-1514.
[11] Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology,2008,47:1473-1482.
[12] Zhao L, Li X, Cheng Y, et al. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir-and entecavir-resistant mutants compared to rtA181T/sW172* mutation. Antiviral Res,2018,154:26-34.
[13] Rose RE, Hernandez D, Falk PJ, et al. Discovery of the novel entecavir-resistant hepatitis B virus reverse transcriptase A181C substitution from an integrated genotypic analysis. Hepatol Commun,2018,2:1123-1135.
[14] Nagasaki F, Niitsuma H, Ueno Y, et al. The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med,2007,213:181-186.

[1]	徐芳, 张海泉, 赵佳强. 低水平HBsAg患者纤维化分期特征及其与血小板的相关性分析[J]. 肝脏, 2021, 26(9): 977-979.
[2]	朱冬明, 丁洁. 二维剪切波弹性成像测量肝脏硬度对慢性乙型肝炎患者肝脏相关事件的预测价值[J]. 肝脏, 2021, 26(9): 990-993.
[3]	陈姣艳, 陈斌, 曹冬容, 朱蔓然, 焦志勇, 秦永军, 夏悯馨. 慢性乙型肝炎并发肝衰竭死亡危险因素的研究[J]. 肝脏, 2021, 26(9): 994-997.
[4]	章晓鹰, 顾超, 马道亮, 张珏, 高月求, 孙学华. HBeAg阴性慢性乙型肝炎患者B、C基因型 HBV S蛋白变异比较[J]. 肝脏, 2021, 26(8): 847-850.
[5]	李兰亚, 伍广, 屠涛, 张丽. 慢性乙型肝炎患者外周血NK细胞水平与肝纤维化的相关性[J]. 肝脏, 2021, 26(8): 879-882.
[6]	王捷骁, 干沁怡, 谢青. HBsAg定量在HBeAg阴性慢性HBV感染患者中的临床应用及价值[J]. 肝脏, 2021, 26(7): 713-716.
[7]	吴宏楷, 邓浩辉, 龚明星, 高洪波, 王战会, 于乐成. 慢性乙型肝炎患者肝内TCR文库在核苷(酸)类似物治疗前后的变化及意义[J]. 肝脏, 2021, 26(7): 742-746.
[8]	谢青, 王文青, 雷青芬, 闫雪华. 慢性乙型肝炎合并布鲁氏杆菌病导致肝硬化1例[J]. 肝脏, 2021, 26(7): 818-819.
[9]	胡侠, 周岳进, 卢成鸿, 潘华将, 王开鉴. 替诺福韦酯治疗恩替卡韦耐药和应答不佳慢性乙型肝炎的临床观察[J]. 肝脏, 2021, 26(6): 614-616.
[10]	段兴刚, 刘立, 刘良婷, 王应甜, 范群雄. 慢性乙型肝炎患者停药导致肝衰竭发生的特征及影响预后的相关因素分析[J]. 肝脏, 2021, 26(6): 617-620.
[11]	李轩, 张丽娜, 王松, 王方, 聂广, 何清. 基线维生素D水平对替诺福韦治疗慢性乙型肝炎疗效的影响[J]. 肝脏, 2021, 26(6): 621-624.
[12]	田颖颖, 丁洁, 徐毅明. FibroScan评价ALT升高慢性乙型肝炎患者抗病毒疗效价值[J]. 肝脏, 2021, 26(4): 381-383.
[13]	季媛媛, 陈艳清, 程琳, 周海东. 凝血酶原时间是慢性乙型肝炎患者肝活检纤维化程度的独立危险因素[J]. 肝脏, 2021, 26(4): 400-402.
[14]	王晴晴, 丁洁, 王辉. HBeAg阳性的慢性乙型肝炎患儿临床治愈的影响因素分析[J]. 肝脏, 2021, 26(4): 439-441.
[15]	张荣荣, 周瑾, 赵鹏, 朱礼尧, 张鑫, 叶晓航. 剪切波弹性成像与血清肝纤维化指标无创评估慢性乙型肝炎患者肝纤维化效能比较[J]. 肝脏, 2021, 26(3): 255-258.